论文部分内容阅读
3月22日,美国FDA批准Taltz(ixekizumab)用于治疗中重度斑块状银屑病成人患者。银屑病是一种自身免疫性皮肤疾病。在有银屑病家族史的患者中,这种疾病的发生率更高,通常见于15~35岁的人。最常见形式的银屑病是斑块状银屑病,此类患者会出现厚厚的红色皮肤,有片状的银白色鳞屑。“今天的批准为斑块状银屑病患者提供了另一种重要的治疗选择,可以帮助缓解疾病导致的皮肤刺激及不适感”FDA药物评价与研究中心药物评价III办公室主任、医学博士Beitz称。
March 22, the United States FDA approved Taltz (ixekizumab) for the treatment of adult patients with severe plaque psoriasis. Psoriasis is an autoimmune skin disease. In patients with a family history of psoriasis, the incidence of this disease is higher, usually seen in people aged 15 to 35 years. The most common form of psoriasis is plaque psoriasis, which presents thick red skin with flaky silver-white scales. “Today’s approval offers another important treatment option for patients with plaque psoriasis that can help to reduce the risk of skin irritation and discomfort caused by the disease.” "FDA Director, Office of Drug Evaluation III, Center for Drug Evaluation and Research, FDA, MD Beitz said.